Ustekinumab for treating active psoriatic arthritis

Technology appraisal guidance
Reference number: TA340
Published: 04 June 2015
Last updated: 03 March 2017

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: final appraisal determination document

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: final appraisal determination document

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: final appraisal determination document
12 March 2015
(280.18 Kb 21 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 09 March 2015